J&J CEO Sees Victory Ahead On Talc, Growth From Johnson's Relaunch
JP Morgan analysts had questions and J&J CEO Alex Gorsky and CFO Joseph Wolk had answers about liability suits alleging that use of the Johnson's brand talcum powder has caused mesothelioma or ovarian cancer. On the Johnson's brand outlook following its relaunch as a natural product line, Gorsky says sales were a key driver in the firm's consumer health sales in the 2018 third quarter. China, meanwhile, is a model for growing sales online, he says.
You may also be interested in...
J&J plans to cut 10% of its consumer health portfolio, with most divestitures in the baby and beauty care segments outside the US. It plans to focus on growing “stronghold” categories of skin health and self care, including Aveeno and Tylenol.
Examples of unfinished business from 2019 include no legislation passed to reform OTC monograph program; FDA putting off until May the planned publication of an NPRM to allow firms to submit OTC NDAs with extra-label information to help guide consumers' self-selection; and no OTC naloxone for opioid overdose approved even after FDA's unprecedented step of developing model DFLs sponsors could use for their own label comprehension studies.
Senator Seeks Trove Of Talc/Asbestos Docs From J&J; FDA On Status Of Lead Acetate Rule; Beauty News In Brief
The Senate Health Committee’s ranking member is “troubled” by a recent Reuters article, requesting numerous documents from J&J related to talc-asbestos testing and the firm’s communications with FDA and consumers on the subject. More beauty news in brief.